Winston Kung
Independent DirectorMr. Winston Kung, M.B.A. serves as Director at Corbus Pharmaceuticals, Inc. since 2025. He serves as a Chief Financial Officer and Treasurer at ArriVent BioPharma, Inc. since January 04, 2024. He is Independent Director of Corbus Pharmaceuticals Holdings, Inc. since August 16, 2024. He serves as a Scientific Advisor at Revelation Capital Management, LLC since April 2024. He serves as Independent Director of Janux Therapeutics, Inc. since September 22, 2022. He served as Scientific Advisor at Revelation Partners, LLC until 2025. He had been Chief Operating Officer and Chief Financial Officer at PMV Pharmaceuticals, Inc. since December 05, 2017 until January 4, 2024. He was employed with PMV Pharmaceuticals, Inc. until March 31, 2024. From April 2013 to November 2017, Mr. Kung worked at Celgene Corporation, a global biopharmaceutical company, where he held multiple positions, including Vice President of Business Development and Global Alliances and Chief Business Officer at Celgene Cellular Therapeutics (a wholly-owned subsidiary of Celgene Corporation). Prior to joining Celgene Cellular Therapeutics, Mr. Kung worked at Citigroup from June 2010 to April 2013 in its Global Healthcare Investment Banking group and at Lehman Brothers (which was subsequently acquired by Barclays) from May 2007 to June 2010 in its Global Mergers and Acquisition Group. Prior to his career in investment banking, from August 2004 to May 2007, Mr. Kung worked at Amgen, as a co-founder of the Alliance Management group and served as the deal lead on multiple acquisitions as part of the Corporate Development group. At Citigroup and Barclays, Mr. Kung worked on various transactions including public and private financings, merger and acquisitions, spin-outs and other financial advisory engagements. Mr. Kung also worked at Genentech, a biotechnology company (acquired by Roche), from November 1999 to September 2002 as part of the Business and Corporate Development group. He served as a Director at Alliqua BioMedical, Inc. since February 15, 2016 until November 24, 2017. Mr. Kung previously served on the board of directors of GNS Healthcare, a private, healthcare artificial intelligence company. He holds a Bachelors of Arts in Biology and International Relations from Brown University and an MBA from Harvard Business School.
Positions
- Company NameJanux Therapeutics, Inc.Stock CodeJANXPositionIndependent DirectorColleagues
- DADavid Alan CampbellPresident, Co-Founder, CEO & Director
- RWRonald W. BarrettIndependent Chairperson
- TDThomas DiraimondoChief Scientific Officer
- JDJaneen DoyleChief Corporate & Business Development Officer
- MWMatt WhitmireVice President of Finance
- MDMaria DobekVice President of Accounting
- JSJake SimsonIndependent Director
- VLVickie L. CappsIndependent Director
- WKWinston KungIndependent Director
- Company NameCorbus Pharmaceuticals Holdings, Inc.Stock CodeCRBPPositionIndependent DirectorColleagues
- YCYuval CohenCEO & Director
- RSRachelle Suzanne JacquesIndependent Chairman of the Board
- SFSean F. MoranChief Financial Officer
- IHIan HodgsonChief Operating Officer
- GSG. Scott GoekenGeneral Counsel & Corporate Secretary
- CBChristina BertschVice President of Human Resources
- JKJohn Kenneth JenkinsIndependent Director
- AAAnne AltmeyerIndependent Director
- WKWinston KungIndependent Director
- Company NameArriVent BioPharma, Inc.Stock CodeAVBPPositionCFO & TreasurerColleagues
- ZYZhengbin YaoCo-Founder, Chairman, President & CEO
- SLStuart LutzkerCo-Founder, President of Research & Development and Director
- RLRobin LaChapelleCo-Founder & COO
- YWYang WangChief Technology Officer
- CWChristian W. NoletIndependent Director
- KPKristine PetersonLead Independent Director
- JAJohn A. HohnekerIndependent Director
